Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NVO

Novo Nordisk ADR

Jan 23 • 04:00PM ET

81.10

Dollar change +0.53
Percentage change 0.66	%

Healthcare • Drug Manufacturers - General • Denmark • NYSE

Peers: LLY PFE MRK ABBV BMY JNJ AMGN REGN GILD VRTX

| Held by: AVDE FVD PPH DFIC APIE PID OZEM DFAI DFAX WINN

Scroll to Statements

Index	-	P/E	26.30	EPS (ttm)	3.08	Insider Own	0.03%	Shs Outstand	3.34B	Perf Week	-2.19%
Market Cap	270.75B	Forward P/E	20.99	EPS next Y	3.86	Insider Trans	0.00%	Shs Float	3.34B	Perf Month	-21.60%
Income	13.78B	PEG	1.09	EPS next Q	0.84	Inst Own	9.99%	Short Float	0.25%	Perf Quarter	-30.88%
Sales	39.33B	P/S	6.88	EPS this Y	16.26%	Inst Trans	-0.77%	Short Ratio	1.12	Perf Half Y	-39.15%
Book/sh	5.40	P/B	15.01	EPS next Y	22.46%	ROA	26.99%	Short Interest	8.30M	Perf Year	-23.12%
Cash/sh	3.36	P/C	24.15	EPS next 5Y	24.09%	ROE	88.20%	52W Range	78.17 - 148.15	Perf YTD	-5.72%
Dividend Est.	1.51 (1.87%)	P/FCF	23.89	EPS past 5Y	16.48%	ROI	53.52%	52W High	-45.26%	Beta	0.44
Dividend TTM	1.45 (1.78%)	Quick Ratio	0.75	Sales past 5Y	16.98%	Gross Margin	84.66%	52W Low	3.75%	ATR (14)	2.74
Dividend Ex-Date	Aug 16, 2024	Current Ratio	0.94	EPS Y/Y TTM	28.07%	Oper. Margin	43.87%	RSI (14)	34.08	Volatility	2.27% 2.22%
Employees	63370	Debt/Eq	0.47	Sales Y/Y TTM	27.73%	Profit Margin	35.03%	Recom	1.74	Target Price	119.94
Option/Short	Yes / Yes	LT Debt/Eq	0.43	EPS Q/Q	23.30%	Payout	36.03%	Rel Volume	0.91	Prev Close	80.57
Sales Surprise	-2.85%	EPS Surprise	0.19%	Sales Q/Q	22.49%	Earnings	Feb 05 BMO	Avg Volume	7.43M	Price	81.10
SMA20	-4.11%	SMA50	-16.77%	SMA200	-33.37%	Trades		Volume	6,761,702	Change	0.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-06-25	Upgrade	Bernstein	Underperform → Mkt Perform
May-30-24	Initiated	Goldman	Buy	$156
Apr-12-24	Initiated	BMO Capital Markets	Outperform	$163
Jan-23-24	Initiated	Morgan Stanley	Overweight	$120
Jan-16-24	Resumed	UBS	Neutral
Dec-01-23	Initiated	Cantor Fitzgerald	Overweight	$120
Oct-02-23	Initiated	Argus	Buy	$110
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-15-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-28-22	Downgrade	UBS	Neutral → Sell
Jun-27-22	Upgrade	Exane BNP Paribas	Underperform → Neutral
Jun-07-22	Upgrade	JP Morgan	Neutral → Overweight
May-31-22	Upgrade	Guggenheim	Neutral → Buy
Apr-25-22	Upgrade	Cowen	Market Perform → Outperform	$130
Apr-12-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Mar-16-22	Upgrade	Deutsche Bank	Hold → Buy
Jan-25-22	Downgrade	Liberum	Hold → Sell
Dec-20-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-17-21	Downgrade	Deutsche Bank	Buy → Hold
Jan-20-21	Downgrade	Credit Suisse	Outperform → Neutral

Show Previous Ratings

Jan-23-25 03:31PM	Why Novo Nordisk (NVO) Is Among the Best Socially Responsible Stocks to Buy According to Hedge Funds? (Insider Monkey)
09:46AM	Eli Lilly Stock Has Tumbled 23% Since Its August High. Is It A Buy Or A Sell? (Investor's Business Daily)
09:30AM	Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
07:38AM	This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly. (Barrons.com)
05:47AM	3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35% (Motley Fool)
05:45PM	Loading…
Jan-22-25 05:45PM	Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts (Zacks)
04:10AM	This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025? (Motley Fool)
Jan-21-25 12:07PM	Novo Nordisk's GLP-1 Drugs: Health Breakthroughs, Big Buybacks, and Medicare's Price-Cut Threat (GuruFocus.com)
11:39AM	Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimers, Study Shows. What It Means for the Stocks. (Barrons.com)
07:32AM	GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings (GuruFocus.com)
05:47AM	Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom? (Motley Fool)
05:00AM	The race for the next Ozempic is on (Quartz)
Jan-20-25 12:16PM	LVMH Surges Past Novo Nordisk as Arnault's Wealth Skyrockets--Is Luxury Back on Track? (GuruFocus.com)
09:32AM	Novo Nordisk A/S - share repurchase programme (GlobeNewswire)
07:03AM	LVMH dethrones Novo Nordisk as Europes most valuable company as Bernard Arnault adds $12 billion to net worth in 2025 (Fortune)
05:39AM	Loading…
05:39AM	Novo Nordisks trial of semaglutide for obesity meets primary endpoint (Clinical Trials Arena)
05:39AM	Novo Nordisks high-dose Wegovy increases weight loss and remains safe (Clinical Trials Arena)
Jan-19-25 05:48PM	Jim Cramers Comments on Novo Nordisk A/S (NVO) Surrounded Its Weight Loss Drugs Being Picked For Medicare Price Negotiations (Insider Monkey)
Jan-18-25 03:45PM	Why Did Novo Nordisk (NVO) Go Down on Friday? (Insider Monkey)
08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
05:32AM	Is Novo Nordisk Stock a Buy? (Motley Fool)
Jan-17-25 06:08PM	Moderna is a 'trade' on Bird Flu vaccine pop, says Mizuho's Jared Holz (CNBC TV) -5.27%
05:03PM	S&P 500 Gains and Losses Today: Intel Stock Soars as Takeover Speculation Spreads (Investopedia)
04:13PM	Medicare to negotiate prices on 15 drugs, including Ozempic (Yahoo Finance Video)
04:07PM	3-Stock Lunch: Intel, Sherwin-Williams & Novo Nordisk (CNBC TV)
04:04PM	Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts (Investor's Business Daily)
02:29PM	Explainer-What Wegovy's inclusion in Medicare price negotiation means for patients, company (Reuters)
01:55PM	Here's How Donald Trump Could Shake Up Health Care And Biotech Stocks (Investor's Business Daily)
01:07PM	Why NVO and LLY Are Dropping Today (Insider Monkey)
12:15PM	Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations (Benzinga)
11:53AM	Loading…
11:53AM	LVMH Regains Title of Europes Most Valuable Stock From Novo (Bloomberg)
11:38AM	Novo Nordisk Stumbles as Eli Lilly Tightens Grip on the Obesity Drug Market (GuruFocus.com)
11:37AM	Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today (Motley Fool)
11:24AM	Analyst Report: Novo Nordisk A/S (Morningstar Research)
11:06AM	Medicare Will Pay Less for Ozempic and Wegovy in 2027. The Price-Negotiation List Is Out. (Barrons.com)
10:17AM	Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks (Yahoo Finance Video)
09:46AM	Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations (Yahoo Finance)
09:20AM	Novo Nordisk CEO attends crisis talks with Danish PM amid Donald Trump Greenland threats (Fortune)
09:13AM	Ozempic could get cheaper as Medicare eyes drug price negotiations and Novo Nordisk stock slips (Quartz)
07:11AM	Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence (GlobeNewswire)
04:05AM	Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025? (Motley Fool)
Jan-15-25 04:23PM	After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst. (Investor's Business Daily)
10:23AM	Eli Lilly: What's Left To Like? A Lot, Says One Analyst. (Investor's Business Daily)
Jan-14-25 03:15PM	Jim Cramer on Novo Nordisk A/S (NVO): Thats Denmarks Jugular (Insider Monkey)
02:00PM	Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected (Yahoo Finance)
02:00PM	Eli Lilly stock down on Q4 guidance miss (Yahoo Finance)
12:12PM	Eli Lilly Shares Down 7.5% as Market Reacts to Slashed Q4 Forecast (GuruFocus.com)
12:11PM	Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday (Motley Fool)
Jan-13-25 05:45PM	Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
09:09AM	2024 was a record year for obesity trials and 2025 is already poised to take over (Clinical Trials Arena)
09:00AM	Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know (Zacks)
08:52AM	Novo Nordisk A/S - share repurchase programme (GlobeNewswire)
Jan-10-25 09:00AM	4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025 (Motley Fool)
Jan-09-25 07:34PM	Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025? (Zacks)
03:36PM	Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea (Investopedia)
03:02PM	Trumps quest for Greenland could make Ozempic even more expensive (CNN Business)
11:05AM	Trumps play for Greenland could make Ozempic more expensive (Quartz)
08:00AM	Is Eli Lilly Stock A Buy Or A Sell After Its Weight-Loss Drug Scores A Major Victory? (Investor's Business Daily)
07:13AM	5 questions facing pharma in 2025 (BioPharma Dive)
04:52AM	Novo Nordisk and Valo expand cardiometabolic drug partnership (Pharmaceutical Technology)
Jan-08-25 04:44PM	Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey (Yahoo Finance)
02:16PM	Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition (GuruFocus.com)
12:47PM	Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone' (Investopedia)
10:06AM	Trump suggests Denmark tariff. How it could hit Novo Nordisk. (Yahoo Finance Video)
10:01AM	Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs (Reuters)
09:45AM	This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly (Motley Fool)
09:45AM	5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher (Barrons.com)
08:35AM	Does Novo Nordisk A/S (NVO) Have an Attractive Valuation? (Insider Monkey)
08:02AM	Novo Nordisk Faces 5 Key Questions, Says Analyst (Barrons.com)
06:30AM	Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases (GlobeNewswire)
02:00AM	Novo Nordisk Needs Answers to These 5 Key Questions (Barrons.com)
01:46AM	3 trial readouts that could shake up the obesity market this year (Pharma Voice)
Jan-07-25 05:45PM	Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
05:32PM	What Trumps Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk (Barrons.com)
03:59PM	Trumps Denmark Tariff Threat Means New Uncertainty for Ozempic Drugmaker Novo Nordisk (Barrons.com)
01:52PM	Trump Is Setting the Global Agenda Again. He Just Flexed His Muscles. (Barrons.com)
01:41PM	Metsera announces positive results in newest Phase IIa GLP-1RA (Clinical Trials Arena)
10:08AM	Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment (Pharmaceutical Technology)
09:30AM	Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet (Zacks)
Jan-06-25 01:00PM	Why 2025 will be an inflection for Novo Nordisk, Eli Lilly's GLP-1s (Yahoo Finance Video)
08:40AM	President-Elect Trump Poses Challenge To U.S. Tech Sales (Investor's Business Daily)
08:00AM	Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug (Benzinga)
Jan-04-25 05:42AM	Better Buy: Novo Nordisk vs. AstraZeneca (Motley Fool)
Jan-03-25 08:20AM	From Davids to Goliaths: the GLP-1RA gold rush (Pharmaceutical Technology)
Jan-02-25 01:14PM	Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks (Benzinga)
12:03PM	Is Eli Lilly Stock A Buy After FDA Pushes Back On Compounded Knockoffs? (Investor's Business Daily)
11:05AM	Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst (Clinical Trials Arena)
09:20AM	US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report (Benzinga)
08:30AM	Should You Buy the Dip in Novo Nordisk Stock Right Now? (Motley Fool)
07:40AM	Tirzepatide outpacing Wegovy in the obesity space (Pharmaceutical Technology)
05:00AM	Weight loss drugs are changing the game, Eli Lilly exec says but many still can't get them (Quartz)
Jan-01-25 09:45AM	Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term (Zacks)
09:00AM	Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock (Zacks)
03:30AM	Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More. (Barrons.com)
Dec-31-24 05:11PM	Historical Trends Warrant a Closer Look at Novo Nordisk (NVO) Call Options (TipRanks)
04:48PM	GLP-1 questions emerge for 2025 (Yahoo Finance)
12:02PM	Novo Nordisk A/S (NVO): A Bull Case Theory (Insider Monkey)
09:52AM	Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. Theres a Clear Winner. (Barrons.com)
Dec-30-24 05:45PM	Why Novo Nordisk (NVO) Dipped More Than Broader Market Today (Zacks)
04:07PM	Is Novo Nordisk A/S (NVO) the Best Pharma Dividend Stock to Buy In 2024? (Insider Monkey)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your FINVIZ experience